BioNTech SE ADR (NASDAQ:BNTX) stock fell 0.38% (As on September 17, 11:15:41 AM UTC-4, Source: Google Finance) after JPMorgan shifted its stance on the company, upgrading the stock from Underweight to Neutral. The adjustment comes with a significant increase in the price target, now set at $125, up from the previous $91. This change reflects the firm’s reaction to BioNTech’s presentation of its oncology pipeline at the European Society for Medical Oncology (ESMO) 2024 event. BioNTech’s updates included promising data from phase II and phase I/II trials for BNT327/PM8002, an anti-VEGF-A/PD-L1 bispecific. The analyst highlighted the need for BioNTech to diversify beyond its COVID-19 vaccine offerings, a sentiment previously echoed by the market concerning Moderna
Prior concerns about BioNTech centered on the absence of sufficient randomized data to support the company’s transition towards its oncology pipeline. The analyst noted that despite the trials for BNT327 being uncontrolled, the encouraging results and parallels drawn from the success of a competing asset, ivonescimab, which has demonstrated randomized data including phase III results, justify a more positive outlook. BNT327 is seen as a potential key driver for BioNTech’s future, offering not only a series of clinical updates in the near term but also significant diversification from the COVID vaccine business later in the decade.
Attention is also directed towards how management plans to strategize the development of BNT327. Last week, the market’s growing appreciation for BNT327’s potential was evident in the stock’s rally.
Despite this recent uptick, the analyst pointed out that BioNTech’s market capitalization still reflects a substantial cash position, suggesting that the current valuation heavily relies on the COVID vaccine business, with modest credit given to the oncology pipeline. Incorporating BNT327 into their financial model with a $5 billion peak sales estimate and a 45% probability of success, JPMorgan has consequently raised their price target for BioNTech.
On the other hand, BioNTech expects revenues for the full 2024 financial year to be in the range of €2.5 to €3.1 billion. The company’s cash and cash equivalents plus security investments as of June 30, 2024, reached €18,485.1 million, comprising €10,376.7 million cash and cash equivalents, €6,916.7 million current security investments and €1,191.7 million non-current security investments. This position increased during the second quarter of 2024 largely attributable to a cash payment received from BioNTech’s collaboration partner Pfizer Inc.